Table 1.
Patient Demographics and Clinical Characteristics
| Demographic or Clinical Characteristic | No. of Patients (N = 37) |
|---|---|
| Age, years | |
| Median | 56 |
| Range | 36-76 |
| ECOG performance status | |
| 0 | 11 |
| 1 | 26 |
| Sex | |
| Male | 23 |
| Female | 14 |
| Previous therapy | |
| Chemotherapy | 30 |
| Radiotherapy | 20 |
| Hormonal | 7 |
| VEGF-targeting agents (antiligand, TKI) | 5 |
| Immunotherapy | 2 |
| Investigational agent | 15 |
| Other | 12 |
| Primary malignancy | |
| Colorectal | 6 |
| Head and neck | 4 |
| Hepatocellular | 3 |
| Pancreas | 3 |
| Carcinoid, esophagus, neuroendocrine, ovary, prostate, melanoma, stomach, uterine (leiomyosarcoma) | 16* |
| Bladder, breast, thyroid (medullary), thyroid (papillary), biliary tract | 5† |
| Tumor response assessment | |
| Measurable disease | 27 |
| Evaluable disease | 10 |
| Prostate | 2 |
| Neuroendocrine | 2 |
| Esophagus | 2 |
| Liver | 1 |
| Colorectal | 1 |
| Thyroid | 1 |
| Melanoma | 1 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor; TKI, tyrosine kinase inhibitor.
*
Two patients had each of the malignancies listed.
†
One patient had each of the malignancies listed.